Clinical trials: Gram-positive Bacterial Infections
Staphylococcal Infections
Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)
The purpose of this study was to evaluate the safety, tolerability, and immunogenicity of the Merck 0657nI S. aureus vaccine (V710) either with or without Merck Aluminum Adjuvant (MAA).
- Trial name
- NCT01324440
- Testing
- V710 (30 µg) with MAA, V710 (30 µg) without MAA
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Clostridioides Difficile Infection
Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection
The goal of this clinical trial is to test whether lyophilized fecal microbime transfer - a dried extract of bacteria from the stool of healthy donors - is better than antibiotic therapy only for treating primary clostridioides…
- Trial name
- DONATE (NCT05709184)
- Testing
- Lyophilized fecal microbiome transfer, Vancomycin
- Where
- 6 sites in Canada, Hungary and 4 more
- Volunteers
- 196 people
- Sponsor
- Rambam Health Care Campus
Pneumococcal Disease
Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)
The primary purpose of this phase 3, single-arm, open-label study is to evaluate the safety and immunogenicity of a 4-dose regimen of V114 administered to healthy infants in South Korea.
- Trial name
- PNEU-PED-KOR (NCT04633226)
- Testing
- V114
- Where
- 19 sites in South Korea
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diphtheria, Tetanus
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.
This study is designed to assess the immunogenicity and safety of PENTAXIM™ combined vaccine versus TETRAXIM™ vaccine to support registration of PENTAXIM™ in South Korea.
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT01214889
- Testing
- PENTAXIM™: DTacP IPV//PRP~T combined vaccine, TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine
- Where
- 14 sites in South Korea
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Sanofi
Mycetoma
Proof-of-Concept Superiority Trial of Fosravuconazole Versus Itraconazole for Eumycetoma in Sudan
This study is a single-center, comparative, randomized, double-blind, parallel-group, active-controlled, clinical superiority trial of Fosravuconazole versus Itraconazole combined with surgery in subjects with eumycetoma in…
- Trial name
- NCT03086226
- Testing
- Fosravuconazole, Itraconazole
- Where
- Sudan
- Volunteers
- 104 people
- Sponsor
- Drugs for Neglected Diseases
Tuberculosis, Multidrug-Resistant, Tuberculosis
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
endTB-Q Clinical Trial is a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of two new, all-oral, shortened regimens for multidrug-resistant tuberculosis…
- Conditions
- Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary Tuberculoses, Mycobacterial Infections
- Trial name
- endTB-Q (NCT03896685)
- Testing
- Bedaquiline 100 MG, Delamanid 50 MG Oral Tablet, Clofazimine 100 MG Oral Capsule
- Where
- 10 sites in India, Kazakhstan and 4 more
- Volunteers
- 323 people
- Sponsor
- Médecins Sans Frontières, France
Diphtheria, Tetanus
Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine
The objective of this study is to compare the Safety and Immunogenicity of a mixed sequence of 2 different pentavalent vaccines (Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib combination Vaccines) with single sequence of…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00674908
- Testing
- Shan 5, Easy Five
- Where
- 3 sites in India
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Shantha Biotechnics Limited
Tuberculosis
Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy Adults
This is a Phase I trial to evaluate the safety and immunogenicity of a ChAdOx1 85A vaccination with and without MVA85A boost in healthy BCG vaccinated adults.
- Trial name
- NCT01829490
- Testing
- ChAdOx1 85A, MVA85A
- Where
- 2 sites in United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis Infection, Healthy Volunteer
Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women
This study is a sub-study of the SSTARLET trial (NCT06498414). The overall aim is to assess the pharmacokinetic profiles after taking a single dose of rifampicin, isoniazid, levofloxacin, rifapentine, and bedaquiline in…
- Conditions
- Tuberculosis Infection, Healthy Volunteer, Breastfeeding
- Trial name
- PRiMe (NCT07069582)
- Testing
- Standard dose rifampicin, High dose rifampicin, Standard dose isoniazid
- Where
- Indonesia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Lung Diseases, Tuberculosis
TB Contact Investigation: Behavioral Intervention
To develop a behavioral intervention aimed at public health workers who perform tuberculosis contact investigation and designed to enhance the contact investigation process.
- Trial name
- NCT00005740
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI)
Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection
This prospective randomized, controlled interventional pilot trial, aims to compare the achievement of the optimal target concentration with continuously administered flucloxacillin (FLU) or cefazolin (CZO) coupled with TDM and…
- Trial name
- TARGET III (NCT05655091)
- Testing
- FLU or CZO as continuous infusion, standard FLU or CZO intermittent bolus administration
- Where
- Switzerland
- Volunteers
- 36 people
- Sponsor
- University Hospital, Basel, Switzerland
HIV Infections, Tuberculosis
Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection
To quantitate in an HIV-infected population the percentage of patients demonstrating the "booster" phenomenon (attainment of a positive response to a second tuberculin purified protein derivative skin test when the first skin…
- Trial name
- NCT00000955
- Testing
- Tuberculin Purified Protein Derivative
- Where
- 14 sites in United States
- Volunteers
- 864 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lung Cancer, Lung Tuberculosis
68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT
Comparison of 68Ga-AlfatideII and 18F-FDG in differential diagnosis effectiveness towards the solitary pulmonary nodules of lung cancer or tuberculosis.
- Trial name
- NCT02481726
- Testing
- 68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG
- Volunteers
- 31 people
- Sponsor
- Xijing Hospital
Staphylococcal Infections
Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections
Clindamycin and rifampicin are authorized in osteoarticular infection treatment (IDSA guidelines) but some interaction is observed. The objective of this study is to evaluate and quantify rifampicin interaction on clindamycin
- Trial name
- DALARI (NCT02782078)
- Testing
- Clindamycin and rifampicin dosages
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pneumococcal Infection
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease…
- Trial name
- NCT05158140
- Testing
- V110, V114, mRNA-1273
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Disease
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.
- Trial name
- NCT04379713
- Testing
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- 97 sites in United States, Argentina and 9 more
- Volunteers
- 1,511 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tuberculosis, Pulmonary
Integrated Discovery and Development of Innovative TB Diagnostics
The long term goal of this project is to provide information critical to the development and use of a low-cost, point-of-care, rapid, simple, and highly accurate diagnostic tool that can help clinicians make a microbiological…
- Trial name
- (CETR) (NCT06624501)
- Testing
- Observational cohort study
- Volunteers
- 1,450 people, healthy volunteers welcome
- Sponsor
- Harvard University Faculty of Medicine
Pneumococcal Disease
A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan
The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in infants and toddlers. This study is enrolling participants who are: Born after at least 36 weeks of pregnancy and about 2 months of…
- Trial name
- NCT05512819
- Testing
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- 11 sites in India, Taiwan
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pertussis, Diphtheria
Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine
Post-marketing evaluation of reactions following receipt of recommended adolescent pertussis vaccine among persons with prior vaccination with acellular vs whole-cell pertussis vaccine.
- Conditions
- Pertussis, Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT00304265
- Testing
- COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)
- Where
- 17 sites in Germany
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumonia, Tuberculosis, Pulmonary
The LalelaLung Study: Digital Stethoscope Clinical Evaluation
Pneumonia is the leading infectious cause of death in children under five years of age worldwide, and most of these deaths occur in low- and middle-income countries.
- Conditions
- Pneumonia, Tuberculosis, Pulmonary, Respiratory Tract Infections, Bronchiolitis
- Trial name
- LaLeLa (NCT07631377)
- Testing
- StethoMe AI-enabled digital stethoscope system, Standard IMCI assessment
- Volunteers
- 350 people
- Sponsor
- Johns Hopkins University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.